The Consolidated Appropriations Act of 2023 (Omnibus) amended the Federal Food, Drug, and Cosmetic Act to require medical device manufacturers to address cybersecurity. As of March 29, 2023, they must provide cybersecurity details in premarket submissions. The Omnibus mandates plans for postmarket cybersecurity vulnerabilities, device cybersecurity demonstrations, and software bill of materials (SBOM) disclosures. Starting October 1, 2023, the FDA will reject submissions not meeting cybersecurity criteria, emphasizing proactive cybersecurity measures.
VW Group’s Enormous Data Leak Reveals Movements of 800,000 EV Owners, Including Trips from Homes to Brothels – DataBreaches.Net
Oi mates, I’ve got some cybersecurity tea to spill today. You know how we always fret about hackers sneaking around, snatching our personal info, right?
